Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
Artigo em Inglês | IMSEAR | ID: sea-148037

RESUMO

Fenofibrate is one of the commonest drug to treat hyperlipidemia in adults (Marshall et al, 2011). However, apart from its hypolipidemic action, it also has the ability to induce bilirubin conjugation. The present study was aimed to find its effect on uncomplicated neonatal hyperbilirubinemia. The study was conducted on 40 normal term newborns who were admitted for uncomplicated jaundice at R.D. Gardi Medical College & Hospital, Ujjain from March 2010 to October 2010. The data included: age, sex, weight, serum bilirubin level, and duration of hospitalization. All newborns enrolled in this study, received phototherapy. The cases were divided into two groups viz. Fenofibrate group (B) consisting of 14 boys (70%) and 6 girls (30%) and a control group (A) with 11boys (55%) and 9 girls (45%). There were no statistical overt differences between the two groups regarding sex distribution, age, weight and total serum bilirubin level at the time of admission. Mean values for total serum bilirubin in Fenofibrate group at 12, 24, 36, and 48 hours after starting of phototherapy were significantly lower than those for control group (p<0.00l). The mean time needed for phototherapy was also shorter in Group B than Group A. Fenofibrate appears to be an effective drug for neonatal hyperbilirubinemia. This decreases the duration of phototherapy and thus reduces the length of hospital stay.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA